On Wednesday, Dollar Tree, Inc. (NASDAQ:DLTR)’s shares inclined 1.49% to $79.72.
Dollar Tree, Inc. (DLTR) an operator of discount variety stores offering merchandise at a fixed price point of $1.00, seems to have a compelling growth story given its progress on the back of endeavors, including store expansion, omni-channel development and penetration into new markets.
However, the stock was let down by its performance in first-quarter fiscal 2015, wherein both top and bottom lines missed the Zacks Consensus Estimate, as sales were hurt by an unfavorable shift in Easter holiday timing and labor disruptions at the West Coast port. Also, the company had to pay incremental freight costs on account of alternate ports.
These headwinds triggered management to tweak its outlook for the fiscal, following which the stock witnessed downward estimate revisions.
Dollar Tree now anticipates sales for the fiscal to be in the range of $9.24–$9.42 billion, contrast with $9.21–$9.45 billion predicted earlier, based on the expectation that comps will grow in a low to low-mid single-digit range in fiscal 2015. Moreover, the company now envisions adjusted earnings per share for fiscal 2015 to be in the band of $3.32–$3.47 contrast with $3.30–$3.50 projected earlier.
Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise at the fixed price of $1.00. The company’s stores provide consumable merchandise, which comprises candy and food, and health and beauty care products; and everyday consumables, such as paper and chemicals, and frozen and refrigerated food. Its stores also offer various merchandise that comprise toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods comprising of Valentine’s Day, Easter, Halloween, and Christmas merchandise.
Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI)’s shares dropped -30.04% to $1.98.
Rock Creek Pharmaceuticals, Inc. (RCPI), a drug development company focused on chronic inflammatory disorders, declared that it has reached definitive agreements with institutional investors to raise about $3.7 million in a registered direct offering of 1,644,500 shares of common stock and warrants to purchase up to 1,223,375 shares of common stock. The shares and warrants will be sold in units, each of which is comprised of one share and 0.75 warrants to purchase one share of common stock. The purchase price per unit in the offering will be $2.25. The warrants will be exercisable six months following the date of issuance and will expire on the fifth anniversary of the initial date that the warrants become exercisable. The warrants will have an exercise price of $2.83.
Rock Creek intends to use the net proceeds from the offering for clinical development activities, working capital, and general corporate purposes.
The securities described above are being offered by the Company following a shelf registration statement on Form S-3 (Registration No. 333-200964), which was declared effective on February 6, 2015 by the Securities and Exchange Commission (SEC). The securities are being offered only by means of a prospectus, counting a prospectus supplement and accompanying base prospectus, forming a part of the effective registration statement. A prospectus supplement and accompanying base prospectus regarding the offering of the shares will be filed with the SEC and will be accessible on the SEC’s website at http://www.sec.gov.
Rock Creek Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health. Its lead drug candidate is anatabine citrate that is in Phase I clinical trials, a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs accessible, such as biologics, steroids, and non-steroidal anti-inflammatories.
At the end of Wednesday’s trade, Crown Castle International Corp (NYSE:CCI)‘s shares surged 0.60% to $82.60.
Crown Castle International Corp (CCI) declared that its Board of Directors has declared a quarterly cash dividend of $0.82 per common share. The quarterly dividend will be payable on June 30, 2015 to common stockholders of record at the close of business on June 19, 2015. Future dividends are subject to the approval of the Company’s Board of Directors.
Crown Castle International Corp., together with its auxiliaries, owns, operates, and leases shared wireless infrastructure in the United States and Australia. The company provides towers and other structures, such as rooftops; and distributed antenna systems, a type of small cell network (small cells).
H & R Block Inc (NYSE:HRB), ended its Wednesday’s trading session with -0.66% loss, and closed at $30.25.
H & R Block Inc (HRB) has signed the Memorandum of Understanding, together with other members of the industry. The MOU documents the agreements of the broad-based working group on detecting and mitigating identity theft tax refund fraud. I commend Commissioner Koskinen for his continued leadership of this unprecedented effort to build a public/private partnership to fight this evolving threat.
H&R Block, Inc., through its subsidiaries, provides tax preparation and related services to the general public primarily in the United States, Canada, and Australia. The company offers assisted income tax return preparation and related services through a system of retail offices operated directly by the company or by franchisees; and online tax services, such as tax advice, professional and do-it-yourself (DIY) tax return preparation, and electronic filing services through its Website hrblock.com.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
